Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1991 1
1996 1
1999 2
2001 1
2008 1
2009 2
2010 2
2011 3
2013 5
2014 4
2015 2
2016 2
2017 6
2018 5
2019 8
2020 5
2021 4
2022 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Strategies and challenges for the next generation of antibody-drug conjugates.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Beck A, et al. Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17. Nat Rev Drug Discov. 2017. PMID: 28303026 Review.
The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug …
The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the ma …
Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H. Xu Y, et al. MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17. MAbs. 2019. PMID: 30543482 Free PMC article. Review.
The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody and Fc-fusion protein drug products and from the lessons learned from many failed development programs over the last three decades. ...
The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody …
Why is there no biosimilar of Erbitux®?
Douez E, D'Atri V, Guillarme D, Antier D, Guerriaud M, Beck A, Watier H, Foucault-Fruchard L. Douez E, et al. J Pharm Biomed Anal. 2023 Sep 20;234:115544. doi: 10.1016/j.jpba.2023.115544. Epub 2023 Jun 22. J Pharm Biomed Anal. 2023. PMID: 37418870 Free article. Review.
Here, we outline the unique structural complexity of this antibody highlighted by advanced orthogonal analytical characterization strategies resulting in risks to demonstrate biosimilarity, which may explain the lack of Erbitux biosimilars in the European and US markets to …
Here, we outline the unique structural complexity of this antibody highlighted by advanced orthogonal analytical characterization strategies …
Dengue Virus Non-Structural Protein 5.
El Sahili A, Lescar J. El Sahili A, et al. Viruses. 2017 Apr 24;9(4):91. doi: 10.3390/v9040091. Viruses. 2017. PMID: 28441781 Free PMC article. Review.
So far, there is no antiviral drug available against dengue, but a vaccine has been recently marketed. Dengue virus also serves as a prototype for the study of other pathogenic flaviviruses that are emerging, like West Nile virus and Zika virus. ...
So far, there is no antiviral drug available against dengue, but a vaccine has been recently marketed. Dengue virus also serves as a …
Antibody-drug conjugates: present and future.
Beck A, Reichert JM. Beck A, et al. MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436. MAbs. 2014. PMID: 24423577 Free PMC article.
Brentuximab vedotin is marketed as therapy for hematological malignancies (Hodgkin lymphoma, systemic anaplastic large cell lymphoma), while ado-trastuzumab emtansine is marketed for treatment of a solid tumor (breast cancer). The approvals of these two ADCs followe …
Brentuximab vedotin is marketed as therapy for hematological malignancies (Hodgkin lymphoma, systemic anaplastic large cell lymphoma) …
State-of-the-Art Electrode Materials for Sodium-Ion Batteries.
Mauger A, Julien CM. Mauger A, et al. Materials (Basel). 2020 Aug 5;13(16):3453. doi: 10.3390/ma13163453. Materials (Basel). 2020. PMID: 32764379 Free PMC article. Review.
This huge effort in research has led and is leading to an important and constant progress in the performance of the SIBs, which have conquered an industrial market and are now commercialized. This progress concerns all the elements of the batteries. ...
This huge effort in research has led and is leading to an important and constant progress in the performance of the SIBs, which have conquer …
Strategies and challenges for the next generation of therapeutic antibodies.
Beck A, Wurch T, Bailly C, Corvaia N. Beck A, et al. Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747. Nat Rev Immunol. 2010. PMID: 20414207 Review.
By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the …
By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful stra …
Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
Heming N, Renault A, Kuperminc E, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Leone M, Timsit JF, Misset B, Benali MA, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Bounab R, Maxime V, Moine P, Bellissant E, Annane D; APROCCHSS investigators; CRICS-TRIGGERSEP network. Heming N, et al. Lancet Respir Med. 2024 May;12(5):366-374. doi: 10.1016/S2213-2600(23)00430-7. Epub 2024 Feb 1. Lancet Respir Med. 2024. PMID: 38310918 Clinical Trial.
METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, fr …
METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa …
Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates.
Bobály B, Fleury-Souverain S, Beck A, Veuthey JL, Guillarme D, Fekete S. Bobály B, et al. J Pharm Biomed Anal. 2018 Jan 5;147:493-505. doi: 10.1016/j.jpba.2017.06.022. Epub 2017 Jun 24. J Pharm Biomed Anal. 2018. PMID: 28688616 Review.
Hydrophobic interaction chromatography (HIC), reversed phase liquid chromatography (RPLC), size exclusion chromatography (SEC) and multidimensional separations are discussed focusing on the analysis of marketed ADCs. Fundamentals and aspects of method development are illus …
Hydrophobic interaction chromatography (HIC), reversed phase liquid chromatography (RPLC), size exclusion chromatography (SEC) and multidime …
60 results